Skip to content
Menu

RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.

RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.

Read at benzinga.com

← All stock news